Antibody-cytokine fusion proteins in clinical trials for the treatment of cancer include various antibody-IL2 fusions [e.g., hu14.18-IL2 (11), huKS-IL2 (12), L19-IL2 (13), F16-IL2 (14), CEA-IL2v (15), NHS-IL2 (16), DI-Leu16-IL2 (17)], as well as fusions with TNF [e.g., L19-TNF (18)] and with IL12 [BC1-IL12 (19) and NHS-IL12 (20)]. This evidence concerns the gene TNF and cancer.